

TAVI in Israel 2008-2013



**David Planer, Haim Danenberg
Hadassah Hebrew University Medical Center
Jerusalem, Israel**



החוג לקרדיולוגיה התערבותית
THE ISRAEL WORKING GROUP ON INTERVENTIONAL CARDIOLOGY

Background

- Trans-catheter aortic valve implantation (TAVI) is an emerging novel technology for the treatment of high-risk AS patients.
- Two commercially available valve systems:




TAVI in Israel: timeline

- First cases:
 - August 2008 – Edwards
 - September 2008 – CoreValve
- January 2010: full reimbursement for TAVI .
- 2011: Establishment of I-TAVI, Israel TAVI ongoing registry.

10 Centers:

- Carmel, Haifa
- Rambam, Haifa
- Rabin, Petach-Tikva
- Tel-Aviv MC, Tel-Aviv
- Sheba, Ramat-Gan
- Wolfson, Holon
- Kaplan, Rechovot
- Shaare Tzedek, Jerusalem
- Hadassah, Jerusalem
- Soroka, Beer Sheba



Israel I-TAVI registry

National I-PAVI Registry - Windows Internet Explorer
http://i-pavi.e-med.co.il/

National I-PAVI Registry

הוֹגָן לְקַרְדִּיוֹלָנוּת הַעֲרוֹבָוִית
THE ISRAEL WORKING GROUP ON INTERVENTIONAL CARDIOLOGY
האיגוד הקרדיולוגי בישראל
ISRAEL HEART SOCIETY

Patient Documents Help Desk Administration Logout
Hello, ADMIN ADMIN

Base line

Patient Details | First initials name: w | Last initials name: s | Hospital: Hadassah | Number at site#: 14 | Valve Brand: Corevalve | Gender: Female

Baseline characteristics

ECG
ECHO-PRE
Angio-PRE
Procedural details
Post-implantation
In Hospital
General information & Status

Euroscore: 40 (%)
STS score: 12
Coronary disease: Yes No
S/A thoracotomy: Yes No
PHT: Yes No 
PA sys pressure: 76 (mmHg)
Pulmonary: Yes No
Porcelain aorta: Yes No
Pacemaker: Yes No
Diabetes: Yes No
Other illnesses: Hepatic Malignancy Other neurologic
 Parkinson PVD S/A CVA
Hemoglobin: 12.4 (g/dl)
Thrombocytes: 323 (n x 1000)
Creatinine: 1.8 (mg%)



Done Internet 100% 59% 23:18



start Inbox - Microsoft Out... Microsoft Excel - Nati... Microsoft PowerPoint: ... National I-PAVI Regis... EN

Collection of data


- All 10 centers: partial data (valve type, approach, mortality)
- 5 centers (700 patients): full clinical and procedural data
- Cross check total numbers with both commerical companies

TAVI in Israel 1.3.2013


- Total implants: 1495



1.4.12-1.3.13
442 pts.



TAVI cases in EU (2011)



Patient Characteristics

Mean +/- SD

Age (years) 82 ± 6

Logistic EuroSCORE (%) 23.3 ± 15

Female 57.3%

BMI 30 (16.4-50)

NYHA
I-II: 5%
III-IV: 95%

DM 30%


Hb (g/dl) 11.8 ± 3.9

Creatinine ($\mu\text{mol/L}$) 1.18 ± 0.67

Baseline Characteristics

AV area (cm ²)	0.66±0.17
AV grad, max (mmHg)	76±23
AV grad, mean (mmHg)	48±16
LVEF (%)	54±10
Annulus (mm)	22.2±2.1
MR (severe, %)	8


TAVI in Israel 1.3.2013




Procedural Parameters

	%
Procedural success	99
Local Anesthesia only	56
TEE	40
Local Anesth only (1.1.12-)	76
2nd valve needed	3

Mortality - 30d.




Overall Mortality - long term



Adverse Events – In Hospital

Death	4.7%
Aortic Dissection	0
Cardiac Tamponade	2%
Access Site Complication	11.2%
Blood transfusion	18%
Myocardial Infarction	0
Pacemaker	21% (29%MDT /6%ES)
Renal Failure	3%
Major Stroke	2.2%
Discharge day (median)	6
>10 d	15%

Change in median NYHA FC



TAVI in Israel – Conclusions:

- Transcatheter Aortic Valve Implantation is rapidly expanding in Israel
- The procedure is safe and effective with favorable results in this complex group of high-risk patients.
- Further expansion of the procedure and its indications and improvement of its results and outcome is awaited.
- Compliance and maintenance of I-TAVI registry is crucial for quality measurements and future directions of this evolving procedure

TAVI: partnership



Thanks



- ...N. Khader, R. Jaffe, A. Elami, A. Kerner, A. Rogouin, G. Bollotin, R. Kornowski, A. Assali, C. Vaknin-Assa , A. Finkelstein, S. Bazan, Y. Ben-Gal, V. Guetta, A. Segev, E. Raanani, V. Turkisher, Y. Almagor, J. Balkin, S. Silberman, C. Lotan, D. Planer, A. Korach, K. George, O. Ayzenberg, G. Gendelman, C. Cafri, A. Abu-Ful, M. Merkin...